Preclinical data demonstrated the robust activity of BE-CAR33 alone and in combination with BE-CAR7 against human CD7 + CD33 + AML cells in a PDX model from a KIT-mutated AML patient.317 Preliminary results from other early clinical trials of CAR-T cell strategies targeting CD33 have shown promising results with acceptable safety profiles.141,313,318. This evidence concerns the gene KIT and acute myeloid leukemia.